Vicapsys Life Sciences Inc
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and … Read more
Vicapsys Life Sciences Inc (VICP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.014x
Based on the latest financial reports, Vicapsys Life Sciences Inc (VICP) has a cash flow conversion efficiency ratio of 0.014x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.43K) by net assets ($-2.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vicapsys Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Vicapsys Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vicapsys Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vicapsys Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Helios Energy Limited
PINK:HLEGF
|
-0.030x |
|
GIIR Inc
KO:035000
|
0.007x |
|
All Cosmos Bio-Tech Holding Corp
TW:4148
|
0.063x |
|
ONCOTHERAPY SCIENCE INC.
F:30O
|
N/A |
|
Tae Kyung Ind
KO:015890
|
0.011x |
|
Surge Battery Metals Inc
PINK:NILIF
|
-0.033x |
|
TAT HONG EQ.SRV. DL-08
F:1Q2
|
N/A |
|
BMS Celik Hasir Sanayi ve Ticaret AS
IS:BMSCH
|
-0.070x |
Annual Cash Flow Conversion Efficiency for Vicapsys Life Sciences Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Vicapsys Life Sciences Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.88 Million | $-121.66K | 0.042x | -80.51% |
| 2023-12-31 | $-1.93 Million | $-417.52K | 0.216x | -13.59% |
| 2022-12-31 | $-950.79K | $-238.20K | 0.251x | -93.14% |
| 2021-12-31 | $-121.65K | $-443.97K | 3.650x | +523.45% |
| 2020-12-31 | $-449.11K | $-262.90K | 0.585x | +118.22% |
| 2019-12-31 | $301.96K | $-970.26K | -3.213x | -139.03% |
| 2018-12-31 | $-253.67K | $-2.09 Million | 8.234x | +112.29% |
| 2017-12-31 | $47.18K | $-3.16 Million | -67.007x | -13237.08% |
| 2009-12-31 | $-2.73 Million | $-1.39 Million | 0.510x | -52.62% |
| 2008-12-31 | $-1.48 Million | $-1.60 Million | 1.077x | -- |